Evidence map›Paper›PMID 38911255›Full record

ArticleOpen medicine (Warsaw, Poland)2024

Immune response analysis of solid organ transplantation recipients inoculated with inactivated COVID-19 vaccine: A retrospective analysis.

Jiazhi Li, Peihua Cao, Zhenhu Chen, Ruihua Deng, Yu Nie, Feixiong Pang, Xiaomian Liu, Haijia Huang, Jianrong Yang, Kebo Zhong and 1 more

Abstract read
In one paragraph

Article in Open medicine (Warsaw, Poland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jiazhi LiDepartment of Transplantation, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning 530021, Guangxi, China.
Peihua CaoClinical Research Center, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, Guangdong, China.
Zhenhu ChenDepartment of Biostatistics, School of Public Health, Southern Medical University, Guangzhou 510280, Guangdong, China.
Ruihua DengDepartment of Transplantation, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning 530021, Guangxi, China.
Yu NieGeneral Surgery Center, Department of Hepatobiliary Surgery II and Transformation Center for Artificial Liver, Institute of Regenerative Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, Guangdong, China.
Feixiong PangDepartment of Transplantation, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning 530021, Guangxi, China.
Xiaomian LiuDepartment of Transplantation, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning 530021, Guangxi, China.
Haijia HuangDepartment of Transplantation, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning 530021, Guangxi, China.
Jianrong YangDepartment of Transplantation, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning 530021, Guangxi, China.
Kebo ZhongGeneral Surgery Center, Department of Hepatobiliary Surgery II and Transformation Center for Artificial Liver, Institute of Regenerative Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, Guangdong, China.
Yanhua LaiDepartment of Biostatistics, School of Public Health, Southern Medical University, Guangzhou 510280, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study aimed to evaluate the efficacy and safety of solid organ transplantation recipients inoculated with an inactivated COVID-19 vaccine. Methods: We retrospectively analyzed the antibody levels and related adverse events of non-transplantation subjects and solid organ transplant recipients, both pre-transplantation (individuals awaiting organ transplantation) and post-transplantation (individuals who have undergone organ transplantation), who received inactivated COVID-19 vaccines from February 2021 to July 2022. Results: The study included 38 pre-transplantation vaccination group, 129 post-transplantation vaccination group, and 246 non-transplantation group. The antibody titer was assessed monthly within the period of 1-12 months after the last injection. The antibody-positive rate among the three groups were 36.84, 20.30, 61.17% ( Conclusion: Inactivated COVID-19 vaccine is safe and effective for solid organ transplantation recipients, at least two doses of which should be completed before organ transplant surgery.

Indexed as

adverse eventsantibodyCOVID-19inactivated COVID-19 vaccinesolid organ transplantation

Identifiers

PMID38911255
PMCPMC11193357

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.